Nurtec® ODT (rimegepant) orally disintegrating tablets 75 mg

You are cordially invited to attend a
Nurtec® ODT (rimegepant) speaker program
sponsored by Biohaven Pharmaceuticals

The First and Only Medication for the Acute and Preventive Treatment of Migraine

PROGRAM OBJECTIVES

- Explore how Nurtec orally disintegrating tablet (ODT) can:
  - Address the current unmet needs for the acute and preventive treatment of migraine
  - Work quickly to resolve pain and return many patients back to normal in 1 hour
  - Demonstrate preventive effect within 1 week
  - Provide sustained pain relief and reductions in migraine days
  - Put the power of migraine control into the hands of healthcare professionals and their patients

We are looking forward to seeing you at this educational program. For additional information, please visit **www.migraineknowledgecenter.com**.

INDICATION

Nurtec® ODT (rimegepant) is indicated in adults for the:

- acute treatment of migraine with or without aura
- preventive treatment of episodic migraine

Program Details

Thursday, January 27, 2022
6:00 PM CT
Superior Grill Highland
7333 Highland Road
Baton Rouge, LA 70808

Registration Information

Please register by going to:
https://www.migraineknowledgecenter.com/?code=YU4WHE

Speaker Information

PANKAJ SATIJA, MD
Director
Pain and Headache Centers of Texas
HOUSTON, TX

Neuroscience Sales Specialist

Wendy Modica
+1 225.921.5466
wendy.modica@biohavenpharma.com

Biohaven Pharmaceuticals is required to disclose all items of value provided to healthcare providers and to disclose these amounts publicly. By attending this speaker program, you are accepting the disclosure of the cost of the meal.

IMPORTANT SAFETY INFORMATION

Contraindications: Hypersensitivity to Nurtec ODT or any of its components.

Warnings and Precautions: If a serious hypersensitivity reaction occurs, discontinue Nurtec ODT and initiate appropriate therapy. Serious hypersensitivity reactions have included dyspnea and rash, and can occur days after administration.

Adverse Reactions: The most common adverse reactions were nausea (2.7% in patients who received Nurtec ODT compared to 0.8% in patients who received placebo) and abdominal pain/dyspepsia (2.4% in patients who received Nurtec ODT compared to 0.8% in patients who received placebo). Hypersensitivity, including dyspnea and rash, occurred in less than 1% of patients treated with Nurtec ODT.

Drug Interactions: Avoid concomitant administration of Nurtec ODT with strong inhibitors of CYP3A4, strong or moderate inducers of CYP3A or inhibitors of P-gp or BCRP. Avoid another dose of Nurtec ODT within 48 hours when it is administered with moderate inhibitors of CYP3A4.

Use in Specific Populations: *Pregnant/breast feeding*: It is not known if Nurtec ODT can harm an unborn baby or if it passes into breast milk. *Hepatic impairment*: Avoid use of Nurtec ODT in persons with severe hepatic impairment. *Renal impairment*: Avoid use in patients with end-stage renal disease.

Please see accompanying full Prescribing Information provided with this invitation.

biohaven pharmaceuticals